CYTOKINETICS INC

Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised or declining. The company's website is www.cytokinetics.com.

The company's first commercial product is MYQORZO (aficamten), a cardiac myosin inhibitor approved by the FDA in December 2025 for treating adults with symptomatic obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms. MYQORZO has also received regulatory approval from the European Commission and China's National Medical Products Administration. The company commenced commercial sales in the United States in the first quarter of 2026 and is preparing for European commercialization beginning in Germany in the second quarter of 2026. Cytokinetics has established licensing agreements with Sanofi for commercialization in China and Taiwan and with Bayer for development and commercialization in Japan.

Behind MYQORZO, Cytokinetics maintains a pipeline of investigational products at discovery, preclinical, and clinical stages. Key pipeline candidates include omecamtiv mecarbil, a cardiac myosin activator in Phase 3 development for heart failure with severely reduced ejection fraction; ulacamten, a cardiac myosin inhibitor in Phase 2 development for heart failure with preserved ejection fraction; and CK-089, a fast skeletal muscle troponin activator in Phase 1 development for muscular dystrophy and other muscle function disorders.

The company's research and development activities center on the biology of the cytoskeleton and muscle contractility, leveraging expertise in cardiac and skeletal sarcomere biology. Cytokinetics has entered into multiple revenue participation agreements with Royalty Pharma entities to fund development of aficamten, omecamtiv mecarbil, and ulacamten, with Royalty Pharma retaining rights to specified percentages of future net sales.

Cytokinetics operates as a specialty biopharmaceutical company with its strategic vision focused on building a leading muscle biology franchise addressing high unmet medical needs in cardiovascular and neuromuscular diseases. The company relies on third-party contract manufacturing organizations for drug supply and manufacturing capabilities.